These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 20363004

  • 1. [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
    Arenere Mendoza M, Manero Ruiz FJ, Carrera Lasfuentes P, Navarro Aznárez H, Pecondón Español A, Rabanaque Hernández MJ.
    Med Clin (Barc); 2010 May 22; 134(15):665-70. PubMed ID: 20363004
    [Abstract] [Full Text] [Related]

  • 2. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 22; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 3. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 22; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 4. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 22; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 5. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Jul 22; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec 22; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 7. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC.
    Ann Rheum Dis; 2008 Sep 22; 67(9):1229-34. PubMed ID: 18174220
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness of TNF antagonists in routine clinical practice and costs].
    Prokes M.
    Vnitr Lek; 2009 Jan 22; 55(1):45-53. PubMed ID: 19227955
    [Abstract] [Full Text] [Related]

  • 9. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 10. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 11. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 May 22; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar 22; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis (ReAct) Study Group.
    Rheumatology (Oxford); 2007 Jul 22; 46(7):1191-9. PubMed ID: 17504821
    [Abstract] [Full Text] [Related]

  • 14. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C.
    Ann Rheum Dis; 2007 Mar 22; 66(3):302-7. PubMed ID: 17079248
    [Abstract] [Full Text] [Related]

  • 15. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians.
    Ann Rheum Dis; 2006 Jun 22; 65(6):746-52. PubMed ID: 16339288
    [Abstract] [Full Text] [Related]

  • 16. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 22; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group.
    Ann Rheum Dis; 2015 May 22; 74(5):890-6. PubMed ID: 24431398
    [Abstract] [Full Text] [Related]

  • 18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec 22; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Dec 22; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    Semin Arthritis Rheum; 2014 Feb 22; 43(4):447-57. PubMed ID: 24012040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.